DiaMonTech AG

  • WKN: A255G4
  • ISIN: DE000A255G44
  • Land: Deutschland

Nachricht vom 16.09.2019 | 09:00

DiaMonTech: Innovative, pain-free blood glucose monitoring to improve the quality of life of diabetes patients in Germany with the help of local pharmacies

DGAP-News: DiaMonTech GmbH / Key word(s): Alliance

16.09.2019 / 09:00
The issuer is solely responsible for the content of this announcement.


DiaMonTech: Innovative, pain-free blood glucose monitoring to improve the quality of life of diabetes patients in Germany with the help of local pharmacies

Berlin, 16 September 2019 - Germany's pharmacists want to ease life for millions of diabetics by offering them pain-free blood glucose monitoring without taking blood as soon as possible. The Deutscher Apothekerverband e. V. (DAV; German Association of Pharmacists) and DiaMonTech GmbH, a young and innovative medical technology company, intend a strategic cooperation to significantly improve the care of diabetes patients and to take an innovative step into the future.

"The Deutscher Apothekerverband is an important partner for us as the umbrella organization with more than 19,000 pharmacies in Germany. The signing of the Letter of Intent confirms the mutual will to cooperate in a trusting and productive manner. Diabetes patients need personal care and access to the latest technology. They should be able to get both from the local pharmacy." says Thorsten Lubinski, co-founder and CEO of DiaMonTech GmbH.

The DAV and DiaMonTech are initially striving to carry out practical tests of the already CE-certified "DMT Base" in selected pharmacies. The "DMT Base" is currently optimized for use in professional environments (e.g. diabetes centers). The patient places his finger on a sensor field for a few seconds and the blood sugar is shown categorized on a display. The blood sugar level can be measured precisely and painlessly without a drop of blood. DiaMonTech thus offers a solution for diabetes patients worldwide that offers them the opportunity to significantly improve their quality of life.

The smaller "DMT Pocket" is currently in development with market launch expected by the end of 2020. This device is supposed to have the size of a smartphone and could therefore become a constant accompaniment for diabetes patients. In Germany alone, around 7.2 million people are currently affected.

About DiaMonTech
DiaMonTech GmbH is a medical technology company that specializes in the development, design and sale of products for medical diagnostics. The patented photothermal diagnostic technology based on infrared lasers enables the precise measurement of relevant blood parameters. The first application is the non-invasive blood glucose measurement, which enables an accurate and fast measurement without pain.

More information about DiaMonTech can be found at www.diamontech.de.

Press contact
Alexander Neblung
Kirchhoff Consult AG
Phone +49 40 60 91 86 70
E-mail diamontech@kirchhoff.de



16.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

Anleihe im Fokus

Deutsche Rohstoff
"Anleihe - Jetzt zeichnen!"

- Emissionsvolumen: bis zu 100 Mio. EUR
- Zeichnungsfrist: 11.11. bis 04.12.2019
- ISIN: DE000A2YN3Q8 / WKN: A2YN3Q
- Börsenesegment: Börse Frankfurt, Open Market (Quotation Board)
- Stückelung / Emissionspreis: 1.000 EUR/ 100%
- Zinssatz (Kupon): 5,25 %
- Laufzeit: 5 Jahre
- Fälligkeit: 5 Jahre / 6.12.2024 (vorbehaltliche vorzeitige Rückzahlung gemäß Anleihebedingungen)
- Zinszahlung: Angebot an Inhaber der 5,625 % Schuldverschreibung 2016/2021 (WKN A2AA05, ISIN DE000A2AA055) diese in die neue Anleihe zu tauschen
- Umtauschfrist: 11.11.2019 – 29.11.2019 (18.00 Uhr)

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Henkel AG & Co. KGaA: Henkel bestätigt Ausblick für das Geschäftsjahr 2019

14. November 2019, 07:30

Aktueller Webcast

EQS Group AG

Conference Call zu den Neunmonatszahlen 2019

15. November 2019

Aktuelle Research-Studie

Uzin Utz AG

Original-Research: Uzin Utz AG (von Montega AG): Kaufen

15. November 2019